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Aim To determine the activity of pseudocholinesterase 
(PChE) in cerebrospinal fluid (CSF) and serum in children 
with solid central nervous system (CNS) tumor and to as-
sess whether PChE activity could be a valid biomarker for 
solid CNS tumors in children.
Methods The study and control group included 30 chil-
dren each. Children in the study group had a solid CNS tu-
mor, while those from the control group had never suffered 
from any tumor diseases. CSF and serum samples were col-
lected from all participants and PChE activity was deter-
mined using the Ellman’s spectrophotometric method. 
PChE activity in CSF was shown as a cerebrospinal fluid/se-
rum ratio expressed in percentage, ie, PChE CSF/serum ra-
tio. Receiver operating characteristic (ROC) curve was used 
to assess whether PChE activity can be used as a biomarker 
for identifying children with solid CNS tumors.
Results Children with solid CNS tumor had significant-
ly higher PChE activity in CSF and serum, as well as PChE 
CSF/serum ratio (P = 0.001). PChE CSF/serum ratio in the 
study group was 2.38% (interquartile range [IQR] 1.14-3.97) 
and 1.09% (IQR 0.95-1.45) in the control group. ROC curve 
analysis of PChE CSF/serum ratio resulted in an area under 
the curve (AUC) value of 0.76 (95% confidence interval [CI] 
0.63-0.88) and a cut-off of 1.09. Twenty five of 29 patients 
with elevated PChE CSF/serum ratio had a tumor, corre-
sponding to a sensitivity of 83% and a specificity of 53%.
Conclusion PChE CSF/serum ratio may be used as a test 
or biomarker with good sensitivity for solid CNS tumors in 
children. Received: May 19, 2013
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Pediatric solid central nervous system (CNS) tumors are 
rarely detected at an early stage. The reasons for this in-
clude the tumor site, acute intracranial bleeding, unavail-
able imaging tests, inconsistent conduct of clinical diag-
nostic procedures, etc (1). CNS tumors account for 20% of 
all childhood cancers, and their incidence rates are rising 
(2). Treatment results are better if the disease is detected 
early, which requires sufficiently sensitive and specific di-
agnostic methods. This is why new biomarkers indicating 
the presence of CNS tumors are needed.
One of the biological materials used for biomarker testing 
is cerebrospinal fluid (CSF) (3). CSF washes the structures of 
the CNS including the tumors present there, enabling the 
detection of tumor proteins in the CSF. PChE has a role in 
tumorogenesis and oncogenesis and has been proven to 
be a good indicator of the presence of tumors (4-6). PChE 
in serum has already been recognized and confirmed as 
a good diagnostic and prognostic marker for head and 
neck tumors (7). Studies of PChE in tumor tissue showed 
that its concentration in some tumor samples was high, 
eg, in glioma tissue samples (4). In tissue samples, PChE 
has higher activity levels in astrocytomas than in medulo-
blastomas, neuromas, or meningeomas (4). It is included 
in the myelin metabolism of, eg, the corpus callosum, ner-
vus opticus, and spinal cord. Subcortical white matter has 
much greater PChE activity than gray matter (8) and PChE 
activity decreases as we descend from the cerebrum to-
ward the spinal cord. After blood removal, PChE activity is 
present in the vessels of the brain and it is higher in arter-
ies than in veins (4)
PChE is an enzyme (EC 3.1.1.8) synthesized in the liver and 
distributed to body tissue and fluids. Cholinesterases (ace-
tylcholinesterase – AChE and PChE) activity changes in an 
abnormal tissue metabolism and/or they become part of 
the oncogenic process (7). Cholinesterase genes are am-
plified, aberrant, and mutated in numerous types of hu-
man tumors. The PChE and AChE found in these tumors 
contain the peptide motif S/T-P-X-Z found in many cdc2 
gene-dependent protein kinase substrates (5). Phosphory-
lation of cdc2-dependent protein kinases is a possible mo-
lecular mechanism that connects cholinesterases with tu-
mor proliferation. Moreover, the inhibition or reduction of 
AChE, PChE, and some other enzymes especially with or-
ganophosphorous and perhaps carbamate poisons used 
as insecticides in home and local environment may result 
in the formation of brain tumors in children partially de-
pending on the genetic polymorphisms that affect in-
secticide metabolism (9,10).
PChE activity in CSF in healthy people is rarely investigat-
ed, most often as a part of studies on specific diseases or 
anesthetics (11-13). Lumbar puncture is an invasive proce-
dure and for ethical reasons the number of healthy par-
ticipants in studies is always small, especially in case of 
children. For this reason the information about the normal 
values of PChE activity in CSF in relation to age at all ages 
is scarce. In adults, PChE activity in CSF ranges from 1/20 
to 1/100 of the value of serum (13). In children, the val-
ues are age-dependent (14). PChE activity in serum is low 
at birth, which is followed by a sudden increase in activity 
over the next three weeks, with values exceeding those in 
adulthood. This remains unchanged until the age of three. 
Between three and six years, PChE activity is 30% above the 
adult level and it begins to slowly drop between the age 
of five and puberty, when it reaches the adulthood value, 
which remains relatively stable (14). In this study, we tested 
whether PChE could be used as a potential biomarker for 
solid CNS tumors in children.
PatientS and MethodS
The study was conducted at the Reference Center for Sol-
id Tumors in Children of the Ministry of Health and Social 
Welfare in Croatia, Children’s Hospital Zagreb, Croatia, be-
tween October 1, 2007 and November 30, 2011. Ethical ap-
proval was received from the Ethics Committee of the Chil-
dren’s Hospital Zagreb. Written consent was obtained for 
each child from their parents, who had been explained the 
study objectives and procedures verbally and in writing.
The number of patients was limited to 60 because we had 
only 60 laboratory kit tests. We had 30 patients with solid 
CNS tumor and 30 patients who met the criteria for the con-
trol group. When all the available laboratory kit tests had 
been used we finished the study. There was a total of 60 par-
ticipants aged between 2 months and 16 years. The study 
group comprised of 30 children with solid CNS tumors. Tu-
mors were classified according to the 2007 World Health Or-
ganization classification (1,15). We divided the study group 
according to tumor classification and histopathological test 
result into gliomas (low-grade and high-grade), ependymo-
mas, embryonal tumors, germ cell tumors, and craniophar-
yngiomas. In the study group 9 children had gliomas, 7 had 
low-grade gliomas, out of whom 1 had an anaplastic gan-
glioglioma, 2 had astrocytomas, and 4 had gliomas. In the 
high-grade glioma group, 2 children had glioblastomas. Five 
children had ependymomas, 14 embryonal tumors, 1 child 
had a germ cell tumor, and 1 child had craniopharyngioma. 
In the embryonal tumor groups, 12 children had medulo-
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blastomas, 1 child had a primitive neuroectodermal tumor, 
and 1 child had an atypical teratoid rhabdoid tumor. All tu-
mors primarily originated from the CNS.
The control group comprised 30 children who had never 
suffered from any tumor diseases. Eight children were hos-
pitalized due to the management of febrile convulsion; after 
a neurotrauma without any sign of hemorrhaging into the 
CNS (7 children); for the replacement of the ventriculoperi-
toneal drain system as a result of growth in case of Arnold 
Chiari malformation (3 children) and Dandy Walker malfor-
mation (4 children); because of the congenital hydrocepha-
lus (6 children); meningomyelocele (1 child); and syringomy-
elia (1 child). We chose these children because each child 
had normal neurological status or only chronic motor handi-
cap; brain CT result showing only anatomical variations, and 
normal biochemical, cytological, and microbiological CSF 
test results. We did not choose random healthy children, 
since they do not have an indication for the lumbar punc-
ture, which would interfere with the ethical principles.
Samples of blood and CSF (both 0.5 µL) were collected at 
the same time, only once from each child. The samples 
were immediately centrifuged and separated from eryth-
rocytes, and then stored at -70°C. We determined PChE ac-
tivity using the Ellman’s spectrophotometric method with 
a Careside TM cholinesterase test system (Careside Inc, Cul-
ver City, CA, USA) using p-hydroxybenzoil choline as a sub-
strate, manufactured by Vitros DT Slides (16).
There was a difference in PChE activity between age 
groups, which was even more pronounced in girls. More-
over, previous measurements of PChE only in CSF showed 
high variability (13). This is why we used PChE CSF/serum 
ratio, presented in percentage, as a variable expected to 
be unaffected by age, sex, or tumor type/pathological de-
velopments.
Cytological evaluation (complete cell count), microbiologi-
cal (bacteriological), and biochemical analysis (glucose in 
mmol/L, Cl in mmol/L, total protein in g/L, and albumin 
fraction in g/L) was performed on CSF obtained by lumbar 
puncture. All drugs taken by the participants at the time of 
sampling were noted.
Statistical analysis
All analyses were performed using the IBM SPSS statisti-
cal package version 20.0 (IBM Corp., Armonk, NY, USA). 
As PChE levels were found not to be normally distribut-
ed, results are reported as median and interquartile rang-
es (IQR). In a skeletal box-and-whisker plot, the whiskers 
are drawn from the quartiles to the extreme values of the 
group. Normality was evaluated with the Kolmogorov-
Smirnov and the Shapiro-Wilk test. Group comparisons 
were performed using the nonparametric Mann-Whitney 
U tests for continuous data and Fisher exact test for cat-
egorical data. As a nonparametric measure of statistical 
dependance between two variables we used Spearman’s 
rank correlation coefficient. The significance level was set 
at P < 0.05. Receiver operator characteristic (ROC) curve 
analysis was used for each of three variables (PChE se-
rum, PChE liquor, and PChE CSF/serum ratio) to determine 
the optimal cut-off point that maximized the desired test 
properties. The optimal cut-off of the investigated pa-
rameters was calculated as the threshold value with the 
highest specificity and sensitivity. For the cut-off points, 
results are presented as sensitivity, specificity, and positive 
and negative predictive values (PPV and NPV). For each 
variable, area under the curve (AUC) of sensitivity plotted 
against 1-specificity is also reported with 95% confidence 
intervals (CI).
ReSuLtS
Groups did not significantly differ by sex (P = 0.795), but 
they did by age (P = 0.001). In the study group, there were 
12 girls and 18 boys between the ages of 2.8 and 16 years 
(median 8.38 years; IQR 4-11.25). In the control group there 
were 16 boys and 14 girls between the ages of 2 months 
and 16 years (3 years; IQR 1.08-6.54).
PChE activity in CSF showed a positive correlation with age 
in the study group (P = 0.037, r = 0.38) and a negative cor-
relation in the control group (P = 0.883, r = -0.03). It was the 
same in the serum (study group, P = 0.057, r = 0.35; control 
group, P =0.259, r = - 0.21). PChE CSF/serum ratio showed 
a positive correlation with age in both study (P = 0.384, 
r = 0165) and control group (P = 0.74, r = 0.063).
In the control group, the median PChE activity in the serum 
was 6488 U/L (IQR, 5202-7772) and in CSF 70 U/L (IQR, 55-93) 
(Figure 1,2). Median PChE CSF/serum ratio was 1.09% (IQR, 
0.95-1.45) and the peak PChE CSF/serum ratio was 2.66% 
(Figure 3). In the study group, the median PChE activity in 
serum was 7505 U/L (IQR 5972-9397) and 202 U/L (IQR 70-
310) in CSF (Figure 1,2). The median PChE CSF/serum ratio 
was 2.38% (IQR 1.14-3.97) and the peak PChE CSF/serum 
ratio was 5.86% (Figure 3). PChE activity in CSF as well as 
PChE CSF/serum ratio were significantly higher in the 
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study than in the control group (PChE in CSF, P = 0.001; PChE 
CSF/serum ratio, P = 0.001). PChE activity in the serum was 
higher in the study group, but not significantly (P = 0.056).
The results indicate high variability of PChE activity in CSF 
in the study group. In this group, we also found a positive 
correlation (r = 0.68) between PChE activity in the serum 
and PChE CSF/serum ratio (P = 0.001). In the control group, 
this correlation was also positive (r = 0.26) but not signifi-
cant (P = 0.167).
Nine children in the study group had gliomas. In this group, 
the PChE CSF/serum ratio variable was between 3 and 
5.86%, and the differences from the control group were the 
most pronounced. PChE CSF/serum ratio and PChE in CSF in 
other tumors were lower than in gliomas (Figure 4,5).
Using a ROC curve analysis we tested PChE in CSF and se-
rum and PChE CSF/serum ratio to determine whether it 
was a suitable variable for identifying the presence of tu-
mors in CNS/CSF. For serum PChE, the AUC was 0.64 (95% 
CI 0.50-0.78), for CSF PChE 0.65 (95% CI 0.55-0.75), and for 
PChE CSF/serum ratio 0.76 (95% CI 0.63-0.88). ROC analy-
sis suggested that the CSF PChE cut-off of 80 U/L (21/30 
patients with tumors had PChE in CSF>80 U/L) could pro-
duce 70% sensitivity, 70% specificity, 70% PPV, and 70% 
NPV. When the cut-off value was further increased to 150 
U/L, all 16 patients with PChE CSF levels >150 U/L were 
FiGuRe 1. Pseudocholinesterase (PChe) activity in serum (u/L) 
in children with solid central nervous system (CnS) tumors and 
control group
FiGuRe 2. Pseudocholinesterase (PChe) activity in cerebro-
spinal fluid (CSF) (u/L) in children with solid central nervous 
system (CnS) tumors and control group
FiGuRe 3. Pseudocholinesterase (PChe) cerebrospinal fluid 
(CSF)/serum ratio (%) in children with solid central nervous 
system (CnS) tumors and control group
FiGuRe 4. Pseudocholinesterase (PChe) activity in cerebrospi-
nal fluid (CSF) (u/L) in various types of solid central nervous 
system (CnS) tumors in children
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positive for solid tumor, corresponding to a specificity of 
100%, sensitivity of 53%, PPV of 100%, and NPV of 68%. 
For PChE CSF/serum ratio, a cut-off of 1.09 was evaluated. 
Twenty-five of 29 patients with elevated PChE CSF/serum 
ratio were positive for tumor, corresponding to a sensitivity 
of 83%, specificity of 53%, PPV of 64%, and NPV of 76%. In 
order to maximize specificity, a cut-off of 2.70% was intro-
duced, corresponding to a specificity of 100%, sensitivity of 
50%, PPV of 100%, and NPV of 67% (Figure 6).
All children in both groups had CSF cytological, biochem-
ical, and microbiological test results within the reference 
range according their age. Their total protein and albu-
min values were also within the reference range. This con-
firmed that other clinical conditions affecting CSF were not 
present in these children.
We registered all drugs taken by children in both groups 
at the time of sampling. In the control group, 21 children 
received no therapy and 9 received medication. Three chil-
dren received ranitidine, 2 valproic acid, 1 child promaz-
ine sodium, 1 cefuroxime, 1 prednisone, and 1 phenobar-
bitone, nitrazepam, pantoprazole, vitamin D3, lactulose, 
and vigabatrin. In the study group, 18 children received no 
therapy. Seven children received ranitidine, 1 hydrocorti-
sone, 1 acyclovir, 1 child fluconazole, 1 trimetoprim sulfo-
metoxazole, and 1 radiotherapy.
diSCuSSion
Our research was first to analyze PChE activity in CSF in 
children with solid CNS tumors and it showed that they 
had higher PChE activity in CSF than children who did 
not have tumors. Our aim was to find a relatively easily 
available biomarker for solid CNS tumors in children that 
would require less invasive methods. Tissue samples from 
the CNS are mainly unavailable, which is why we chose 
to test CSF, which is in direct contact with the brain struc-
tures. Around 528 proteins secreted by a tumor have been 
identified in CSF to date (17), many of which are studied as 
potential biomarkers (3,17).
There are several limitations of this study. Research was 
conducted in the Children’s Hospital Zagreb, which is the 
Reference Centre for Solid Tumors in Children of the Min-
istry of Health and Social Welfare in Croatia. Due to the 
size of Croatian population, collecting a larger number 
of examinees would require considerably more time. For 
this reason, different types of solid CNS tumors were in-
cluded in the study. Also, groups differed by age, although 
it is known that PChE activity is different in different age 
groups (14). Considering the age of our participants, we 
expected PChE activity to be higher in the control group 
because of their younger age (14). Still, PChE activity was 
significantly higher in the study group. Correlation of age 
and PChE activity in CSF and serum was positive in the 
case group, ie, older children had greater PChE activity 
in both serum and CSF. This further supports the as-
FiGuRe 5. Pseudocholinesterase (PChe) cerebrospinal fluid 
(CSF)/serum ratio (%) in various types of solid central nervous 
system (CnS) tumors in children
FiGuRe 6. Receiver operating characteristic (RoC) curves for predicting solid 
central nervous system (CnS) tumor in children based on pseudocholinesterase 
(PChe) activity in serum, cerebrospinal fluid (CSF), and PChe CSF/serum ratio
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sumption that PChE activity was indeed higher due to the 
presence of tumors.
Participants in both groups received drugs that could have 
affected PChE activity. Antiepileptic drugs or sedatives are 
acting as AChE and PChE inductors in the serum (18,19), 
while ranitidine and hydrocortisone lower PChE activity 
(17,20,21). Their effect diminished the differences between 
the groups rather than augmented them, as was expected. 
PChE activity in CSF and serum was much higher in the 
study group and maybe it would have been higher had 
it not been affected by hydrocortisone and ranitidine. In 
the control group, PChE activity maybe would have been 
lower had they not taken antiepileptic therapy.
The variability of PChE activity in CSF was higher in chil-
dren with tumors. We believe that this is a result of dif-
ferences between tumor types, especially in relation to 
glioma tissue. Cavanagh et al showed that glioma tissue 
had high PChE concentration levels (4). In our study, pa-
tients with gliomas also had the highest PChE activity val-
ues. These differences require further study. To rule out 
any influence of the physiology and pathology of the ex-
aminees, we calculated CSF/serum PChE ratio, which was 
significantly higher in the study group. In conclusion, this 
study indicates that PChE activity in CSF expressed as a 
CSF/serum PChE ratio can be used to detect solid CNS tu-
mors in children.
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